TCL1 expression patterns in Waldenström macroglobulinemia.
The oncogenic role of TCL1 in chronic lymphocytic leukemia is well established in transgenic mice. TCL1 expression in other B-cell malignancies has been also described: post-germinal center-derived malignancies, such as multiple myeloma, classically do not express TCL1. Waldenström macroglobulinemia is a post-germinal center malignancy that is known to be similar to chronic lymphocytic leukemia in terms of its gene expression profile. TCL1 expression has not been so far assessed in Waldenström macroglobulinemia. Transcriptomic explorations show that TCL1A expression is linked to signaling pathways and biological functions that are known to be involved in Waldenström macroglobulinemia as well as to gene signatures of interest in B-cell malignancies. We investigated TCL1 expression at the protein level in the bone marrow of a series of 59 patients with Waldenström macroglobulinemia: 76% of patients expressed TCL1, which appeared to be associated with a pejorative prognostic impact. TCL1 could have an oncogenic role in Waldenström macroglobulinemia, and deserves further exploration.
CHU Clermont-Ferrand, Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, F-63003 Clermont-Ferrand, France.|Clermont Université, Université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Richard
R
Lemal
CHU Clermont-Ferrand, Service d'Anatomie Pathologique, F-63003 Clermont-Ferrand, France.
Sandrine
S
Bard-Sorel
CHU Clermont-Ferrand, Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, F-63003 Clermont-Ferrand, France.|Clermont Université, Université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Laura
L
Montrieul
CHU Clermont-Ferrand, Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, F-63003 Clermont-Ferrand, France.|Clermont Université, Université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Jacques-Olivier
JO
Bay
CHU Clermont-Ferrand, Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, F-63003 Clermont-Ferrand, France.|Clermont Université, Université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Aurélie
A
Ravinet
CHU Clermont-Ferrand, Service d'Anatomie Pathologique, F-63003 Clermont-Ferrand, France.
Albane
A
Ledoux-Pilon
Plateforme Bio-informatique Paris Descartes, Institut Necker Enfants Malades (INEM), Paris, France.
Nicolas
N
Cagnard
CHU Clermont-Ferrand, Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, F-63003 Clermont-Ferrand, France.|Clermont Université, Université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Sébastien
S
Bailly
Service d'Hématologie, CH, Lens, France.
Pierre
P
Morel
APHP Hôpital Pitié-Salpêtrière, Anatomie Pathologique, Paris, France.
Frédéric
F
Charlotte
Service des Maladies du Sang, Hôpital Huriez, CHRU Lille, Lille, France.|U837 INSERM, IRCL, CHRU, Lille, France.
Xavier
X
Leleu
Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, France.|Laboratoire d'Hématologie, Centre de Biologie et Pathologie, CHRU Lille, France.|INSERM UMR 1172, IRCL, Lille, France.
Stéphanie
S
Poulain
Clermont Université, Université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Pierre J
PJ
Déchelotte
Department of Clinical Hematology, Necker Hospital, Paris, France.|INSERM UMR 1163, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France.|Paris Descartes Sorbonne Paris Cité University, Imagine Institute, Paris, France.
Olivier
O
Hermine
APHP Hôpital Pitié-Salpêtrière, Hématologie, Paris, France.|UPMC Paris 6, GRC-11, GRECHY, Paris, France.
Véronique
V
Leblond
CHU Clermont-Ferrand, Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, F-63003 Clermont-Ferrand, France.|Clermont Université, Université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Olivier
O
Tournilhac
CHU Clermont-Ferrand, Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, F-63003 Clermont-Ferrand, France.|Clermont Université, Université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
Romain
R
Guièze
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000378:metabolism* / Q000473:pathology; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D015996:Survival Rate; D008258:Waldenstrom Macroglobulinemia / Q000378:metabolism* / Q000401:mortality / Q000473:pathology
D011518:Proto-Oncogene Proteins; C090851:TCL1A protein, human